Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels of 92.5% at Russian trial -Ifax

[beijingwalker]

Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels of 92.5% at Russian trial -Ifax
By Reuters Staff
JANUARY 14, 20215:25 PM

FILE PHOTO: Vials of a COVID-19 vaccine candidate, a recombinant adenovirus vaccine named Ad5-nCoV, co-developed by Chinese biopharmaceutical firm CanSino Biologics Inc and a team led by Chinese military infectious disease expert, are pictured in Wuhan, Hubei province, China March 24, 2020. China Daily via REUTERS


MOSCOW (Reuters) - Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

Ad5-nCoV is a candidate vaccine co-developed by CanSino Biologics and a Chinese military-backed research unit.

Chinese COVID-19 vaccine Ad5-Ncov shows high antibody levels at Russian trial -Ifax

Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies, the Interfax news agency reported.

www.reuters.com